Prevalence of obesity and bronchial asthma is increasing in industrialized countries. Several studies have suggested a relationship between these disorders. Evidence comes from studies with animal models as well as epidemiologic observations. Moreover, pulmonary function parameters, genetic and hormonal factors support the hypothesis that obesity and asthma are linked. Given the enormous economic impact effective and efficient treatment strategies for both diseases are important. The present review will describe patents and recent developments in drugs directed against obesity and asthma. Potential therapeutic targets include the ORL-1 receptor, the LPA receptor, the VEGF receptor, cannaboid receptor, T cells, and protein kinases.